^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Multiple Myeloma

    1d
    Cytokine-Treated Veto Cells in Treating Patients With Hematologic Malignancies Following Stem Cell Transplant (clinicaltrials.gov)
    P1/2, N=16, Active, not recruiting, M.D. Anderson Cancer Center | Trial completion date: Dec 2025 --> Dec 2027 | Trial primary completion date: Dec 2025 --> Dec 2027
    Trial completion date • Trial primary completion date
    |
    cyclophosphamide • fludarabine IV
    1d
    NCI-2020-09704: Low-Dose Selinexor and Choline Salicylate for Non-Hodgkin or Hodgkin Lymphoma, Histiocytic/Dendritic Cell Neoplasm, or Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov)
    P1, N=22, Active, not recruiting, Mayo Clinic | Trial completion date: Aug 2027 --> Jun 2026
    Trial completion date
    |
    Xpovio (selinexor)
    1d
    MUKEight: Phase II Randomised Trial of Cyclophosphamide & Dexamethasone in Combination With Ixazomib in Relapsed or Refractory Multiple Myeloma. (clinicaltrials.gov)
    P2, N=112, Completed, University of Leeds | Unknown status --> Completed | Trial completion date: Jan 2021 --> Jan 2025
    Trial completion • Trial completion date
    |
    lenalidomide • bortezomib • cyclophosphamide • Ninlaro (ixazomib) • thalidomide
    1d
    CARTIFAN-1: A Study of LCAR-B38M CAR-T Cells, a Chimeric Antigen Receptor T-cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Chinese Participants With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov)
    P2, N=123, Terminated, Nanjing Legend Biotech Co. | Active, not recruiting --> Terminated; The study was terminated early due to a strategic realignment of the sponsor's business plan, not related to safety, efficacy, or data integrity concerns.
    Trial termination • IO biomarker
    |
    Carvykti (ciltacabtagene autoleucel)
    2d
    PrE1005: Belantamab Mafodotin or Daratumumab With Bortezomib, Lenalidomide and Dexamethasone for Newly Diagnosed Multiple Myeloma (clinicaltrials.gov)
    P3, N=500, Not yet recruiting, PrECOG, LLC.
    New P3 trial
    |
    lenalidomide • bortezomib • Darzalex Faspro (daratumumab and hyaluronidase-fihj) • Blenrep (belantamab mafodotin-blmf)
    2d
    Mobilization of Stem Cells With Motixafortide (BL-8040) in Combination With G-CSF in Multiple Myeloma Patients (clinicaltrials.gov)
    P3, N=60, Recruiting, Guangzhou Gloria Biosciences Co., Ltd. | Not yet recruiting --> Recruiting | Trial completion date: Dec 2026 --> May 2027 | Trial primary completion date: Aug 2026 --> Dec 2026
    Enrollment open • Trial completion date • Trial primary completion date
    |
    Aphexda (motixafortide)
    2d
    Health Through Activity: A Pilot Study of a Rehabilitation Intervention for People Living With Multiple Myeloma (clinicaltrials.gov)
    P=N/A, N=5, Completed, MGH Institute of Health Professions | Active, not recruiting --> Completed | N=20 --> 5 | Trial completion date: Feb 2026 --> Mar 2025 | Trial primary completion date: Feb 2026 --> Mar 2025
    Trial completion • Enrollment change • Trial completion date • Trial primary completion date
    2d
    CarMob: Carfilzomib Based Chemotherapy Mobilization for Autologous Stem Cell Transplants in Multiple Myeloma (clinicaltrials.gov)
    P1, N=18, Recruiting, Hackensack Meridian Health | Trial completion date: Oct 2025 --> Sep 2026 | Trial primary completion date: Oct 2025 --> Sep 2026
    Trial completion date • Trial primary completion date
    |
    cyclophosphamide • carfilzomib • melphalan • Neupogen (filgrastim) • dexamethasone injection
    2d
    The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas (clinicaltrials.gov)
    P2, N=27, Not yet recruiting, Mayo Clinic
    New P2 trial
    2d
    MOMENTUM: A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov)
    P2, N=100, Not yet recruiting, C4 Therapeutics, Inc.
    New P2 trial
    |
    dexamethasone • cemsidomide (CFT7455)
    3d
    Application of individualized low-protein diet nursing for managing multiple myeloma patients with renal impairment. (PubMed, Medicine (Baltimore))
    After 1 year, the ILPD group showed improved albumin levels, stable body mass index, better renal function, reduced C-reactive protein, and higher quality of life scores, with fewer adverse events compared to controls. ILPD nursing significantly benefits renal function, nutrition, and quality of life while reducing adverse events in MM patients with renal impairment, representing a feasible and effective management strategy.
    Observational data • Retrospective data • Journal
    |
    CRP (C-reactive protein)
    3d
    Alcohol consumption and risk of cancer: a Mendelian randomization analysis of four biobanks and consortium data. (PubMed, BMC Med)
    We observed moderate-to-weak evidence supporting causal effects of alcohol consumption on risk of head/neck, oesophageal, and colorectal cancer, inconsistent evidence for liver cancer, and no evidence for breast cancer. Overall, human genetic data do not provide evidence that alcohol consumption is a cause of all cancers and suggest there may even be inverse associations with certain cancer types.
    Journal
    |
    ADH1B (Alcohol Dehydrogenase 1B (Class I), Beta Polypeptide)